Jynarque is owned by Otsuka.
Jynarque contains Tolvaptan.
Jynarque has a total of 2 drug patents out of which 0 drug patents have expired.
Jynarque was authorised for market use on 23 April, 2018.
Jynarque is available in tablet;oral dosage forms.
The generics of Jynarque are possible to be released after 07 April, 2030.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8501730||OTSUKA||Process for preparing benzazepine compounds or salts thereof|| |
(3 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10905694||OTSUKA||Pharmaceutical solid preparation comprising benzazepines and production method thereof|| |
(7 years from now)
|Orphan Drug Exclusivity (ODE)||Apr 23, 2025|
Market Authorisation Date: 23 April, 2018
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic